Which generation of targeted drugs does Mobotinib belong to?

Mobocertinib (Mobocertinib), trade nameExkivity, is an oral tyrosine kinase inhibitor (TKI) that targets specific EGFR (epidermal growth factor receptor) mutations. It belongs to the third generation of EGFR targeted drugs, mainly targeting EGFR gene exon 20 insertion mutation (Exon 20 insertion) patients with non-small cell lung cancer (NSCLC).

The third generationEGFR-TKI was originally designed to overcome the resistance problems existing in the first two generations of EGFR targeted drugs (such as gefitinib, erlotinib, afatinib, etc.), especially the resistance caused by the T790M mutation. Mobosetinib is unique in its high selectivity and effectiveness against exon 20 insertion mutations. Exon 20insertion mutations are a rare and challenging type of EGFR mutations that are generally insensitive to the first two generations of EGFR-TKI, while mobosetinib (mobosetinib) can effectively inhibit tumor growth caused by this mutation.

Mobotinib irreversibly binds EGFR mutant protein and inhibits its tyrosine kinase activity, thereby blocking the signaling pathway of cancer cells and inhibiting the growth and spread of tumor cells. Compared with other TKIs, mobotinib (mobosetinib) can target mutated EGFR proteins more specifically while reducing inhibition of wild-type EGFR, which helps reduce adverse drug reactions.

Clinical trials show thatmobotinib (mobosetinib) is effective in treatingEGFRexon20Insertion mutationNSCLC patients showed significant efficacy. Although patients with this type of mutation are clinically rare, the emergence of mobosetinib provides them with a new treatment option. Common side effects include diarrhea, rash, stomatitis, abnormal liver function, and pneumonia. Patients need to be closely monitored during use to manage these adverse reactions.

In general, as a third-generation EGFR targeted drug, the development and application of mobotinib (mobosetinib) marks another important progress in the EGFR-TKI treatment field, providing new treatment hope for NSCLC patients with specific mutation types.